EUVIMEDEUVIMED entdecken
Crossref

Standard or Modified Gemcitabine Plus Nab-Paclitaxel (GnP) in the First-Line Treatment of Patients with Metastatic Pancreatic Adenocarcinoma (MPA): A Single-Center Analysis

Victor Hugo Fonseca de Jesus, Francisco de Assis Maia Jr, Cícero Gonzaga Santos, Tiago Cordeiro Felismino, Marcos Pedro Guedes Camandabora

Brazilian Journal of Oncology · 05.06.2026 · 22 (CP)

DOI: 10.1055/s-0045-1814366 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brazilian Journal of Oncology, erschienen am 05.06.2026. Verfasst von Victor Hugo Fonseca de Jesus und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Gemcitabine plus nab-paclitaxel (GnP) is one of the standard chemotherapy regimens in the management of metastatic pancreatic adenocarcinoma (MPA). Little information is available on the real-world effectiveness and safety of GnP in Latin Americans and the role of modified GnP in this population. Materials and Methods This is a retrospective, unicentric study. We included chemotherapy-naïve patients with MPA diagnosed from 2015 to 2022 who started first-line with GnP. We compared the clinical characteristics, treatment outcomes, and safety profiles of patients treated with standard or modified GnP.

Results

The study population consisted of 52 patients. Those treated with standard GnP had less comorbidity as measured by Charlson Comorbidity Index (median: 0 vs. 1; p = 0.023). Overall response and disease control rates were 28.6 and 57.1% in the standard GnP arm and 11.8 and 58.8% in the modified GnP, respectively. There were no differences in median overall survival (10.1 vs. 12.1 months; p = 0.739) or median progression-free survival (6.4 vs. 5.7 months; p = 0.306). Patients treated with modified GnP had numerically lower rates of grades 3 or higher neutropenia (28.6 vs. 5.9%; p = 0.078) and thrombocytopenia (20.0 vs. 0.0%; p = 0.081).

Conclusion

The activity and safety profiles of GnP in this Latin American cohort are comparable to those seen in other populations. The modified regimen is associated with similar clinical effectiveness and lower chances of hematological toxicity, when compared with standard GnP.

Zitieren

APA

Jesus, V. H. F. D., Jr, F. D. A. M., Santos, C. G., Felismino, T. C., & Camandabora, M. P. G. (2026). Standard or Modified Gemcitabine Plus Nab-Paclitaxel (GnP) in the First-Line Treatment of Patients with Metastatic Pancreatic Adenocarcinoma (MPA): A Single-Center Analysis. Brazilian Journal of Oncology, 22(CP). https://doi.org/10.1055/s-0045-1814366

Vancouver

Jesus VHFD, Jr FDAM, Santos CG, Felismino TC, Camandabora MPG. Standard or Modified Gemcitabine Plus Nab-Paclitaxel (GnP) in the First-Line Treatment of Patients with Metastatic Pancreatic Adenocarcinoma (MPA): A Single-Center Analysis. Brazilian Journal of Oncology. 2026;22(CP). doi:10.1055/s-0045-1814366

BibTeX
@article{Jesus2026,
  author = {Jesus, Victor Hugo Fonseca de and Jr, Francisco de Assis Maia and Santos, Cícero Gonzaga and Felismino, Tiago Cordeiro and Camandabora, Marcos Pedro Guedes},
  title = {Standard or Modified Gemcitabine Plus Nab-Paclitaxel (GnP) in the First-Line Treatment of Patients with Metastatic Pancreatic Adenocarcinoma (MPA): A Single-Center Analysis},
  journal = {Brazilian Journal of Oncology},
  year = {2026},
  volume = {22},
  number = {CP},
  doi = {10.1055/s-0045-1814366}
}
Kostenlos starten →